The first once-daily oral JAK inhibitor
Baricinix (baricitinib) is a selective JAK1 and JAK2 inhibitor for moderate to severe active rheumatoid arthritis and severe alopecia areata.
Approved indications
Baricitinib is indicated across immune-mediated conditions where a targeted oral therapy is needed.
Rheumatoid Arthritis
For moderate to severe active RA in adults with inadequate response to one or more DMARDs — as monotherapy or with methotrexate.
Learn moreAlopecia Areata
The first once-daily pill for adults with severe alopecia areata — a common autoimmune disorder causing unpredictable hair loss.
Learn more
Global Patient Support Program
Life saving drugs are either beyond the reach of general people or not available in many countries. Because of the patent exemptions for Bangladeshi companies, Beacon Pharmaceuticals can manufacture the patented drugs to support the global patients.
Registered & Licensed in Bangladesh
By the regulatory authority of Bangladesh
- Baricinix 2
- Marketing Authorization No. 341-346-058
- Baricinix 4
- Drug Registration No. 4-341-347-058
Ready to order Baricinix?
Place your order online or reach our team for any question.